TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06111885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days
Study: NCT04683692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Testing
Description: Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
Study: NCT05493592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standardized physical activity protocol associated with the consumption of Cajanus cajan (EXACAJAN)
Description: Supervised re-training by an Adapted Physical Activity (APA) professional combined 100 g of pigeon peas 3 times a week~Physical activity protocol is standardized. It's the same than in the control arm.~The preparation of pigeon peas and their consumption will be standardized in terms of species cultivated, geographical origin and culinary preparation.~A follow-up of the food intakes standardized plus follow-up logbook, recording the weekly pigeon pea intake, will also be filled out by the participant. The addition of 100 grams of pigeon peas to the diet corresponds to an intake of about 980 mg of polyphenols, 360 mg of carotenoids and 570 mg of vitamin C (24). Thus, the patient's diet will be fortified with approximately 420 mg of polyphenols per day. This level of polyphenol supplementation is known to have beneficial effects on human health.
Study: NCT04692792

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50 mL) per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dai Dai flower drink
Description: consume 1 bottle (50 mL) per day for 8 weeks
Study: NCT05321355

Intervention type: DEVICE
Intervention: Implantation of vagus nerve stimulation according to clinical indication
Description: no interventions, only observation

Intervention type: DEVICE
Intervention: Implantation of vagus nerve stimulation according to clinical indication
Description: no interventions, only observation
Study: NCT06631417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: formulation 3
Study: NCT04001179

Intervention type: OTHER
Intervention: Pulmonary embolism diagnosis by nuclear medicine imaging
Description: nuclear medicine imaging

Intervention type: OTHER
Intervention: Pulmonary embolism diagnosis by nuclear medicine imaging
Description: nuclear medicine imaging
Study: NCT05749055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-102
Description: Selective GABA-A alpha2,3,5 positive allosteric modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05101070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-531011
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-531011
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-531011
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-531011
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered by intravenous infusion
Study: NCT04931641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Description: Prebiotic galacto-oligosaccharides (GOS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Description: 50 mg iron as ferrous fumarate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous fumarate
Description: 50 mg iron as ferrous fumarate
Study: NCT06213038

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106
Description: SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Study: NCT05336136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom mask
Description: Custom mask based on 3D facial photograph for administration of non-invasive ventilation
Study: NCT05325190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Patch System
Description: Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
Study: NCT05782361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.
Study: NCT04913688

Intervention type: PROCEDURE
Intervention: bedside ultrasound performed group
Description: If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, an emergency physician performs bedside ultrasound of lower extremities to the patients agreed to participate in this study. The patients also are examined duplex ultrasound by radiologist.
Study: NCT05076669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stoma follow-up
Description: delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: routine management of stoma
Study: NCT05336136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current commercial mask
Description: Current commercial mask used for administration of non-invasive ventilation
Study: NCT06481033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Time fMRI Neurofeedback
Description: The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
Study: NCT06643754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3276
Description: Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Study: NCT05555615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
Study: NCT05462353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg of ASC41
Description: ASC41 tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of ASC41 (2 tablets of 2 mg ASC41)
Description: ASC41 tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally once daily.
Study: NCT06274970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocols
Description: Aforementioned in the detailed description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Protocols
Description: Conventional protocols for non-ERASP group Eg: No preoperative vitamin D and calcium supplementation etc.
Study: NCT04852068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
Description: Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program
Description: Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program
Description: Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program
Description: Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
Study: NCT05682144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Plasmablasts (B cells)
Description: Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
Study: NCT06373289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: higher oxygen saturation target using Nellcor pulse oximetry sensors
Description: The intervention will be a cross over exposure to the higher oxygen saturation target.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lower oxygen saturation target using Nellcor pulse oximetry sensors
Description: The intervention will be a cross over exposure to the lower oxygen saturation target.
Study: NCT04958031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-871 1.0 mg
Description: CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-871 3.0 mg
Description: CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD, oral (tablet), once per day for 12 weeks
Study: NCT04680026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker
Study: NCT04954794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
Study: NCT04680026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline
Study: NCT05964608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Structured interviews, consisting of a total of 6 sessions, were held once every two weeks for men with premature ejaculation problems. Behavioral therapy took place once every two weeks for a total of six 45-minute sessions. The stop-start technique was the therapy used. Behavioral therapy interviews were conducted at the urology outpatient clinic of the hospital. Post-tests were administered to men with premature ejaculation (PEDT) and their spouses (FSFI and SQOL-F) immediately after the 6th session was completed.
Study: NCT02080429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Descent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pushing
Study: NCT06287632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recruitment/ITP-CPAP (Intervention A)
Description: Participant will receive a recruitment maneuver followed by CPAP set to the level of end-expiratory esophageal pressure (measured during atmospheric pressure breathing). The intervention will last for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP (Intervention B)
Description: Participant will receive their home CPAP (if on CPAP at home) or CPAP at 8-10 cmH20 (if not on CPAP at home or no known diagnosis of OSA). The intervention will last for 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Atmospheric Pressure
Description: Participant will breathe at atmosphere pressure (no CPAP) with supplemental oxygen as needed per clinical guidance.
Study: NCT03561376

Intervention type: DRUG
Group type: OTHER
Intervention: Topical zinc oxide vs. petrolatum post-surgical scars
Description: Following linear closure on non-scalp skin with scar length \> 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery.
Study: NCT06526143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M2VA Pain Care Pathway (M2VAPCP)
Description: M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M2VA Pain Care Pathway (M2VAPCP)
Description: M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation
Description: Implementation facilitation teams consisting of internal and external facilitators will conduct activities for two purposes:~1. to build working relationships within the pain and addiction care pathways to achieve the shared goal of implementing high-quality M2VAPCP; and~2. to promote constructive, problem-solving oriented communication based on indicators of M2VAPCP implementation progress.~Activities will include Virtual Site Visits, all-side facilitation team meetings, local facilitation team meetings, M2VAPCP consultation groups, learning collaboratives, case identification reports and audit and feedback.